Table 1.
Demographic and clinical characteristics of RRMS patients
| Age | Sex | EDSS | Relapses in the last 2 years | Treatment | DMT before wash out | |
|---|---|---|---|---|---|---|
| Active patients | ||||||
| MS1 | 43 | F | 3 | 3 | WO | Avonex |
| MS2 | 46 | M | 3·5 | 2 | NT | NT |
| MS3 | 50 | F | 3·5 | 3 | WO | Tysabri |
| MS4 | 34 | F | 6 | 3 | WO | Tysabri |
| MS5 | 25 | F | 6 | 2 | WO | Glatiramer Acetate |
| MS6 | 30 | F | 3 | 2 | WO | Rebif |
| MS7 | 31 | F | 4 | 3 | NT | NT |
| MS8 | 36 | F | 4 | 2 | WO | Avonex |
| MS9 | 43 | M | 3 | 2 | NT | NT |
| MS10 | 43 | F | 3·5 | 2 | WO | Avonex |
| MS11 | 40 | F | 4 | 3 | WO | Fingolimod (FTY720) |
| MS12 | 54 | M | 3 | 2 | WO | Avonex |
| MS13 | 46 | F | 3 | 2 | WO | Avonex |
| MS14 | 27 | M | 3·5 | 3 | WO | Tysabri |
| Stable patients | ||||||
| MS15 | 32 | F | 1 | 0 | NT | N/A |
| MS16 | 27 | F | 1 | 0 | NT | N/A |
| MS17 | 30 | M | 1·5 | 0 | NT | N/A |
| MS18 | 47 | M | 1·5 | 0 | NT | N/A |
| MS19 | 32 | F | 1 | 0 | NT | N/A |
| MS20 | 33 | F | 1·5 | 0 | NT | N/A |
| MS21 | 37 | F | 1·5 | 1 | NT | N/A |
| MS22 | 28 | F | 1 | 0 | NT | N/A |
| MS23 | 53 | F | 3 | 1 | NT | N/A |
| MS24 | 25 | F | 1·5 | 0 | NT | N/A |
| MS25 | 29 | F | 1·5 | 0 | NT | N/A |
| MS26 | 55 | M | 2 | 0 | NT | N/A |
| MS27 | 40 | F | 1·5 | 0 | NT | N/A |
| MS28 | 48 | F | 2 | 1 | NT | N/A |
| MS29 | 43 | F | 2 | 0 | NT | N/A |
| MS30 | 32 | F | 1·5 | 0 | NT | N/A |
| MS31 | 34 | F | 1·5 | 0 | NT | N/A |
| MS32 | 38 | F | 2 | 1 | NT | N/A |
| MS33 | 35 | M | 2 | 1 | NT | N/A |
| MS34 | 37 | F | 1·5 | 1 | NT | N/A |
| MS35 | 45 | F | 2 | 0 | NT | N/A |
EDSS, Expanded Disability Status Scale; DMT, disease modified therapy; NT, not treated; WO, wash out; NA, not applicable.